Markets:

Overview

News

Currencies

International

Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

286.38 -6.51 (-2.22%)

Streaming Delayed Price Updated: 11:12 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference

June 02, 2022

From Insulet Corporation

Via Business Wire

Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia

June 01, 2022

From Insulet Corporation

Via Business Wire

Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks ↗

May 31, 2022

The deal would have been transformative, but may have limited teamwork in the space.

Via Investor's Business Daily

Looking Into Insulet's Return On Capital Employed ↗

May 26, 2022

According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.

Via Benzinga

Expert Ratings for Insulet ↗

May 06, 2022

Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings:

Via Benzinga

How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space ↗

May 24, 2022

One analyst called the rumored deal "transformative," but says the timing is unfavorable.

Via Investor's Business Daily

PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition ↗

May 24, 2022

Insulet (PODD) stock is heading higher on Tuesday as investors react to reports that DexCom (DXCM) is considering acquiring the company.

Via InvestorPlace

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg ↗

May 24, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ↗

May 24, 2022

Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning!

Via InvestorPlace

Citigroup Maintains Buy Rating for Insulet: Here's What You Need To Know ↗

May 17, 2022

Citigroup has decided to maintain its Buy rating of Insulet (NASDAQ:PODD) and lower its price target from $350.00 to $310.00. Shares of Insulet are trading up 1.23% over the last 24 hours, at $199.34...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

May 17, 2022

Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday.

Via Benzinga

Recap: Insulet Q1 Earnings ↗

May 05, 2022

Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by...

Via Benzinga

Insulet Announces CEO Transition

May 05, 2022

From Insulet Corporation

Via Business Wire

Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year

May 05, 2022

From Insulet Corporation

Via Business Wire

Insulet’s 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose

May 02, 2022

From Insulet Corporation

Via Business Wire

Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes ↗

April 27, 2022

Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with...

Via Benzinga

Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes

April 27, 2022

From Insulet Corporation

Via Business Wire

Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022

April 07, 2022

From Insulet Corporation

Via Business Wire

Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20% ↗

February 24, 2022

Insulet Corp's (NASDAQ: PODD) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million, exceeding the consensus of $301.06 million. The company...

Via Benzinga

Recap: Insulet Q4 Earnings ↗

February 23, 2022

Insulet (NASDAQ:PODD) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet...

Via Benzinga

Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year

February 23, 2022

From Insulet Corporation

Via Business Wire

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

Earnings Scheduled For February 23, 2022 ↗

February 23, 2022

Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Insulet to Present at Upcoming Investor Conferences

February 16, 2022

From Insulet Corporation

Via Business Wire

Insulet Promotes Inclusivity for People with Diabetes through Nintendo® Video Game Animal Crossing™: New Horizons

February 17, 2022

From Insulet Corporation

Via Business Wire

Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine

February 07, 2022

From Insulet Corporation

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022 ↗

February 03, 2022

Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗

February 02, 2022

Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗

January 31, 2022

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.